ALM301

Modify Date: 2024-04-06 16:02:03

ALM301 structure	Common Name	ALM301
	CAS Number	1313439-71-2	Molecular Weight	415.48
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₅H₂₅N₃O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of ALM301

ALM301 is an orally active highly specific AKT inhibitor with IC50 values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth[1].

Name	ALM301

Description	ALM301 is an orally active highly specific AKT inhibitor with IC50 values of 0.13 µM, 0.09 µM and 2.75 µM for AKT1, AKT2 and AKT3, respectively. ALM301 inhibits AKT phosphorylation and modulates downstream signalling in vitro. ALM301 can inhibit cancer cell proliferation and tumor growth[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> PI3K/Akt/mTOR >> Akt
Target	AKT1:0.13 μM (IC50) Akt2:0.09 μM (IC50) Akt3:2.75 μM (IC50)
In Vitro	ALM301 (0.001-10 µM; 72 h) inhibits the proliferation of cancer cells, and PI3KCA-mutant MCF-7 cells is the most sensitive; increases sub-G0 population in a dose-dependent manner[1]. ALM301 (1 µM; 1 h) inhibits AKT phosphorylation in MCF-7 and sustains up to 48 h, with an EC50 value of 0.47 µM[1]. Cell Proliferation Assay[1] Cell Line: MCF-7, T47D, NCI-H460, HCT116 and other cancer cells Concentration: 0.001-10 µM Incubation Time: 72 h Result: Inhibited the proliferation of cancer cells, and PI3KCA-mutant MCF-7 cells was the most sensitive with an IC50 of 2.25 µM. Western Blot Analysis[1] Cell Line: MCF-7 Concentration: 0.001-10 µM Incubation Time: 1, 4, 24 and 48 h Result: Inhibited pAKT and pGSK3β at various concentrations and timepoints up to 48 h.
In Vivo	ALM301 (10, 30 and 100 mg/kg; p.o.; single dosage) inhibits pAKTS473 in tumors and suppresses tumor growth[1]. ALM301 (3 or 10 mg/kg; p.o.; q.d. for 49 days) shows better tumor inhibition ability when combined with Tamoxifen (HY-13757A)[1]. Animal Model: BALB/c mice (bearing A549 xenografts)[1] Dosage: 10, 30 and 100 mg/kg Administration: p.o.; single dosage Result: Increased total plasma concentrations dose-dependently that resulted in almost total abrogation of measurable pAKTS473 in tumors at all timepoints over 24 h. Exhibited the tumour growth inhibition (TGI) of 23, 31 and 41% at 10, 30 and 100 mg/kg, respectively. Animal Model: BALB/c mice (bearing PIK3CA-mutant MCF-7 xenografts)[1] Dosage: 3 or 10 mg/kg Administration: p.o.; q.d. for 49 days Result: Showed significant tumour regressions of 57% and 50% at 3 and 10 mg/kg, respectively, when combined with Tamoxifen (HY-13757A) (5 mg/kg; q.d.).